Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-Oral Fluoroquinolone Triple Regimen for Osteoarticular Brucellosis
NCT07887152Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Shihezi University
- Start
- Nov 2026
- Primary completion
- Oct 2028
01
Overview
Randomised, open-label trial of levofloxacin and moxifloxacin in osteoarticular brucellosis (OB) (3 arms), sponsored by The First Affiliated Hospital of Shihezi University. Primary endpoint: Clinical cure rate at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
levofloxacinmoxifloxacin
03
Conditions
osteoarticular brucellosis (OB)
Beyond the preview
Go deeper on NCT07887152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07887152.